PURPOSE: A polysaccharide-flavonoid conjugate was developend and proposed for the treatment of pancreatic ductal adenocarcinoma (PDAC). METHODS: The conjugate was synthesized by free radical grafting reaction between catechin and dextran. The chemical characterization of the conjugate was obtained by UV-Vis, 1H-NMR, FT-IR and GPC analyses, while the functionalization degree was determined by the Folin-Ciocalteu assay. The biological activity of the catechin-dextran conjugate was tested on two different cell lines derived from human pancreatic cancer (MIA PaCa-2 and PL45 cells), and the toxicity towards human pancreatic nestin-expressing cells evaluated. RESULTS: Both the cancer cell lines are killed when exposed to the conjugate, and undergo apoptosis after the incubation with catechin-dextran which resulted more effective in killing pancreatic tumor cells compared to the catechin alone. Moreover, our experimental data indicate that the conjugate was less cytotoxic to human pancreatic nestin-expressing cells which are considered a good model of non-neoplastic pancreatic cells. CONCLUSION: The suitability of newly synthesized Dextran-Catechin conjugate in the treatment of PDAC was proved confirming the high potential application of the proposed macromolecula system in the cancer therapy.
PURPOSE: A polysaccharide-flavonoid conjugate was developend and proposed for the treatment of pancreatic ductal adenocarcinoma (PDAC). METHODS: The conjugate was synthesized by free radical grafting reaction between catechin and dextran. The chemical characterization of the conjugate was obtained by UV-Vis, 1H-NMR, FT-IR and GPC analyses, while the functionalization degree was determined by the Folin-Ciocalteu assay. The biological activity of the catechin-dextran conjugate was tested on two different cell lines derived from humanpancreatic cancer (MIA PaCa-2 and PL45 cells), and the toxicity towards humanpancreatic nestin-expressing cells evaluated. RESULTS: Both the cancer cell lines are killed when exposed to the conjugate, and undergo apoptosis after the incubation with catechin-dextran which resulted more effective in killing pancreatic tumor cells compared to the catechin alone. Moreover, our experimental data indicate that the conjugate was less cytotoxic to humanpancreatic nestin-expressing cells which are considered a good model of non-neoplastic pancreatic cells. CONCLUSION: The suitability of newly synthesized Dextran-Catechin conjugate in the treatment of PDAC was proved confirming the high potential application of the proposed macromolecula system in the cancer therapy.
Authors: H Oettle; M Arning; U Pelzer; D Arnold; C Stroszczynski; J Langrehr; P Reitzig; M Kindler; J Herrenberger; R Musch; E W Korsten; D Huhn; H Riess Journal: Ann Oncol Date: 2000-10 Impact factor: 32.976
Authors: J M Meerum Terwogt; W W ten Bokkel Huinink; J H Schellens; M Schot; I A Mandjes; M G Zurlo; M Rocchetti; H Rosing; F J Koopman; J H Beijnen Journal: Anticancer Drugs Date: 2001-04 Impact factor: 2.248
Authors: P A Vasey; S B Kaye; R Morrison; C Twelves; P Wilson; R Duncan; A H Thomson; L S Murray; T E Hilditch; T Murray; S Burtles; D Fraier; E Frigerio; J Cassidy Journal: Clin Cancer Res Date: 1999-01 Impact factor: 12.531
Authors: Sami Makharza; Orazio Vittorio; Giuseppe Cirillo; Steffen Oswald; Elizabeth Hinde; Maria Kavallaris; Bernd Büchner; Michael Mertig; Silke Hampel Journal: Pharm Res Date: 2014-12-24 Impact factor: 4.200
Authors: Giuseppe Cirillo; Maria Vittoria Mauro; Umile Gianfranco Spizzirri; Paolina Cavalcanti; Francesco Puoci; Cristina Giraldi; Orazio Vittorio; Nevio Picci; Francesca Iemma Journal: J Mater Sci Mater Med Date: 2013-10-09 Impact factor: 3.896